Systemic lupus erythematosus with juvenile onset: current status of the problem (literature review) ; Системная красная волчанка с ювенильным началом: современное состояние проблемы (обзор литературы)

The article was prepared within the framework of the basic scientific topic №1021051302580-4.; Статья подготовлена в рамках фундаментальной научной темы №1021051302580-4.

IMA-PRESS, LLC

2024

Modern Rheumatology Journal / Современная ревматология

application/pdf

https://mrj.ima-press.net/mrj/article/view/1568/1464; Levy DM, Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345-64. doi:10.1016/j.pcl.2012.03.007.; Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Feb;71(2):290-301. doi:10.1002/art.40697.; Асеева ЕА, Лила АМ, Соловьев СК и др.Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21.; Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019 Dec:209:108274. doi:10.1016/j.clim.2019.108274. Epub 2019 Oct 31.; Huang JL, Yao TC, See LC. Prevalence ofpediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective populationbased study in Taiwan. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):776-80.; Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2021. http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf; Alexander T, Hedrich CM. Systemic lupuserythematosus – Are children miniature adults? Clin Immunol. 2022 Jan:234:108907. doi:10.1016/j.clim.2021.108907. Epub 2021 Dec 8.; Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi:10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.; Kwon YC, Chun S, Kim K, Mak A. Updateon the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. Cells. 2019 Sep 30;8(10):1180. doi:10.3390/cells8101180.; Kuo CF, Grainge MJ, Valdes AM, et al. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26. doi:10.1001/jamainternmed.2015.3528.; Sestan M, Kifer N, Arsov T, et al The Roleof Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus. Curr Issues Mol Biol. 2023 Jul 17;45(7): 5981-6002. doi:10.3390/cimb45070378.; Caielli S, Wan Z, Pascual V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol. 2023 Apr 26: 41:533-560. doi:10.1146/annurev-immunol101921-042422. Epub 2023 Feb 28.; Ardoin SP, Daly RP, Merzoug L, et al;Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019 Jul 1;17(1):32. doi:10.1186/s12969-0190327-4.; Yu H, Nagafuchi Y, Fujio K. Clinical andImmunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi:10.3390/biom11070928.; Li H, Wang T, Li B, et al. Bioinformaticanalysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023 Aug 30;12(8):1517-1526. doi:10.21037/tp-23-365. Epub 2023 Aug 21.; Ambrose N, Morgan TA, Galloway J, et al;UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016 Dec;25(14):1542-1550. doi:10.1177/0961203316644333; Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021 Jun;36(6):1377-1385. doi:10.1007/s00467-020-04686-1; Hsu TC, Yang YH, Wang LC, et al. Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. Pediatr Rheumatol Online J. 2023 Mar 24;21(1):28. doi:10.1186/s12969-023-00806-x; Chan EY, Lai FF, Ma AL, Chan TM. Managing Lupus Nephritis in Children and Adolescents. Paediatr Drugs. 2023 Dec 20. doi:10.1007/s40272-023-00609-3. Online ahead of print.; Appenzeller S, Pereira DR, Julio PR, et al. Neuropsychiatric manifestations in childhoodonset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022 Aug;6(8):571-581. doi:10.1016/S2352-4642(22)00157-2.; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023 Aug 9;10(1):5. doi:10.1186/s40348-023-00161-7.; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177.; Hiraki LT, Benseler SM, Tyrrell PN, et al.Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009 Nov;36(11): 2539-46. doi:10.3899/jrheum.081141. Epub 2009 Oct 15.; Watson L, Leone V, Pilkington C, et al;UK Juvenile-Onset Systemic Lupus Erythematosus Study Group. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012 Jul;64(7):2356-65. doi:10.1002/art.34410.; Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020 Apr;29(5):474481. doi:10.1177/0961203320909156. Epub 2020 Mar 31.; Massias JS, Smith EM, Al-Abadi E, et al.Clinical and laboratory phenotypes in juvenileonset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr; 30(4):597-607. doi:10.1177/0961203320984251. Epub 2021 Jan 7.; Alperin JM, Ortiz-Fernandez L, Sawalha AH.Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018 Oct 30:9:2496. doi:10.3389/fimmu.2018.02496.eCollection 2018.; Harley ITW, Sawalha AH. Systemic lupuserythematosus as a genetic disease. Clin Immunol. 2022 Mar;236:108953. doi:10.1016/j.clim.2022.108953; Misztal MC, Liao F, Couse M, et al. Genome-Wide Sequencing Identified Rare Genetic Variants for Childhood-Onset Monogenic Lupus. J Rheumatol. 2023 May;50(5):671-675. doi:10.3899/jrheum.220513. Epub 2022 Nov 15.; Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020 Mar 5;9(3):712. doi:10.3390/jcm9030712.; Al-Mayouf SM, Alkhars F, AlSaleem A. Phenotype and disease course differences in monogenic and sporadic childhood lupus. Lupus. 2023 Nov;32(13):1548-1554. doi:10.1177/09612033231211065. Epub 2023 Oct 25.; Belot A, Rice GI, Omarjee SO, et al; FREX Consortium; GENIAL Investigators; UK JSLE Study Group. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020 Feb;2(2):e99-e109. doi:10.1016/S2665-9913(19)30142-0. Epub 2020 Jan 13.9; Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127. doi:10.1007/s00109016-1465-5. Epub 2016 Sep 27.; Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 Nov;146(5): 925-937. doi:10.1016/j.jaci.2020.08.017.; Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021 Jan;80(1):109-117. doi:10.1136/annrheumdis-2020-218636; Al-Mayouf SM, Alreefi HA, Alsinan TA, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021 Nov;31(6): 1171-1178. doi:10.1080/14397595.2021.1886627. Epub 2021 Feb 22.; Sawada T, Fujimori D, Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunol Med. 2019 Mar;42(1):1-9. doi:10.1080/25785826.2019.1628466. Epub 2019 Jun 17.; Hoyt KJ, Chatila TA, Notarangelo LD, et al. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 Feb:211:108326. doi:10.1016/j.clim.2019.108326. Epub 2019 Dec 12.; Sharifinejad N, Azizi G, Chavoshzadeh Z,et al. Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features. Front Immunol. 2022 Dec 5:13: 1023127. doi:10.3389/fimmu.2022.1023127.eCollection 2022.; Li YR, Li J, Zhao SD, et al. Meta-analysisof shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015 Sep;21(9):1018-27. doi:10.1038/nm.3933. Epub 2015 Aug 24.; Molano-Gonzalez N, Rojas M, Monsalve DM, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019 Mar:98:24-32. doi:10.1016/j.jaut.2018.11.002. Epub 2018 Nov 17.; Malagуn C, Gomez MDP, Mosquera C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019 Apr; 18(4):369-381. doi:10.1016/j.autrev.2018.11.006. Epub 2019 Feb 14.; Setoue DN, Pitta AC, Fiorot FJ, et al; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhoodonset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018 Aug;17(8):836-839. doi:10.1016/j.autrev.2018.03.009. Epub 2018 Jun 7.; Lythgoe H, Lj M, Hedrich CM, Aringer M.Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022 Jan:234:108898. doi:10.1016/j.clim.2021.108898. Epub 2021 Nov 29.; Batu ED, Akca UK, Kisaarslan AP, et al.The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. J Rheumatol. 2021 Jun;48(6): 907-914. doi:10.3899/jrheum.200871. Epub 2020 Nov 15.; Chang LS, Huang PY, Kuo HC, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022 Sep; 21(9):103144. doi:10.1016/j.autrev.2022.103144. Epub 2022 Jul 13.; Ohara A, Iwata N, Sugiura S, et al. Evaluation of the European League Against Rheumatism/American College of Rheumatology-2019 classification criteria in patients with childhood-onset systemic lupus erythematosus: a single-center retrospective study. Clin Rheumatol. 2022 Aug;41(8):2483-2489. doi:10.1007/s10067-022-06138-7. Epub 2022 Apr 4.; Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus. Clin Rheumatol. 2022 Sep;41(9):2721-2727. doi:10.1007/s10067-022-06209-9. Epub 2022 May 19.; Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE-towards a comprehensive management plan. Nat Rev Rheumatol. 2011 Apr;7(4):225-33. doi:10.1038/nrrheum.2011.15. Epub 2011 Mar 8.; Aragon E, Resontoc LP, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016 Apr;25(4):399-406. doi:10.1177/0961203315 615220. Epub 2015 Nov 3.; Smith EMD, Tharmaratnam K, Al-Abadi E,et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022 Aug 3;61(8):33783389. doi:10.1093/rheumatology/keab915.; Chen YC, Hsu CY, Tsai MC, et al. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023 Oct 27:11:1272065. doi:10.3389/fped.2023.1272065. eCollection 2023.; Falcini F, Nacci F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus. 2007;16(8):613-7. doi:10.1177/0961203307078973.; Groot N, de Graeff N, Avcin T, et al.European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi:10.1136/annrheumdis-2016210960. Epub 2017 Jun 19.; Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2989-96. doi:10.1002/art.22048.; Ozturk K, Caglayan S, Tanatar A, et al;PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021 Nov;30(13):2144-2150. doi:10.1177/09612033211054399. Epub 2021 Nov 1.; Na Nakorn K, Piyaphanee N, Sukharomana M, et al. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023 Jun;42(6):16551664. doi:10.1007/s10067-023-06533-8. Epub 2023 Feb 13.; Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023 Apr;10(1): e000834. doi:10.1136/lupus-2022-000834.; Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.; Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):16371641. doi:10.1136/annrheumdis-2016211001. Epub 2017 May 4.; Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 2. Вопросы современной педиатрии. 2018;17(2):110-25.; Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi:10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi:10.1007/s40272-02100457-z. Epub 2021 Jul 10.; Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022 Oct;4(10):883-889. doi:10.1002/acr2.11482. Epub 2022 Jul 24.; Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022 Jul 27:13:940416. doi:10.3389/fimmu.2022.940416. eCollection 2022.; Lim LSH, Pullenayegum E, Lim L, et al.From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi:10.1002/acr.23199. Epub 2017 Sep 26.; Smith E, Al-Abadi E, Armon K, et al.Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi:10.1177/0961203319836712. Epub 2019 Mar 14.; Brunner HI, Vadhariya A, Dickson C, et al.Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul; 10(2):e000817. doi:10.1136/lupus-2022000817.; Mao Y, Yin L, Huang H, et al. Addition ofcyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan; 47(1):105-113. doi:10.1177/0300060518796751. Epub 2018 Sep 12.; Jansson AF, Sengler C, KuemmerleDeschner J, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011 Jan;30(1):87-97. doi:10.1007/s10067-010-1630-0. Epub 2010 Dec 1.; Merino-Vico A, Frazzei G, van Hamburg JP,Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023 Jan;53(1):e2149675. doi:10.1002/eji.202149675. Epub 2022 Nov 16.; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛПи др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. [; Mahmoud I, Jellouli M, Boukhris I, et al.Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Aug:187:213-219.e2. doi:10.1016/j.jpeds.2017.05.002.; Sawhney S, Agarwal M. Rituximab use inpediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi:10.1177/09612033211034567. Epub 2021 Jul 27.; Каледа МИ, Никишина ИП, Николаева ЕВ и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214; Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi:10.1177/0961203320981137; Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase Cδ. Pediatr Rheumatol Online J. 2018 Sep 26;16(1): 61. doi:10.1186/s12969-018-0278-1.; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021; 59(4):367-383.; Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020 Jun 25:14:2503-2513. doi:10.2147/DDDT.S216193.eCollection 2020.; Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.; Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2014 Apr; 41(4):759-67. doi:10.3899/jrheum.130690. Epub 2014 Mar 15.; Ramaswamy M, Tummala R, Streicher K,et al. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci. 2021 Oct 19;22(20):11286. doi:10.3390/ijms222011286.; Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi:10.1001/jamanetworkopen.2023.38200.; Pin A, Tesser A, Pastore S, Moressa V, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20): 7767. doi:10.3390/ijms21207767.; Chuprin J, McCormack L, Richmond JM,Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 Mar;18(3):263-272. doi:10.1080/1744666X.2022.2047022. Epub 2022 Mar 4.; Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi:10.3389/fimmu.2023.1288675.eCollection 2023.; https://mrj.ima-press.net/mrj/article/view/1568

10.14412/1996-7012-2024-2-95-102

Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).

edsbas.B8D68CBB